Acrivon CEO buys 49,000 company shares

Acrivon Therapeutics’ President and CEO, Dr. Peter Blume-Jensen, reported buying 49,000 shares of common stock on January 14, 2026, in an open-market purchase at a weighted average price of $1.676 per share.

Rhea-AI Filing Summary

Acrivon Therapeutics’ President and CEO, Dr. Peter Blume-Jensen, reported buying 49,000 shares of common stock on January 14, 2026, in an open-market purchase at a weighted average price of $1.676 per share. The trades were executed in multiple lots at prices ranging from $1.66 to $1.68 per share. Following this transaction, he directly holds 2,095,771 common shares.

The filing also reports 314,706 common shares held indirectly through co-founder and EVP Dr. Kristina Masson. Footnotes state that Dr. Masson disclaims beneficial ownership of Dr. Blume-Jensen’s directly held shares, and Dr. Blume-Jensen likewise disclaims beneficial ownership of Dr. Masson’s shares, except to the extent of each spouse’s pecuniary interest.

Insider Trade Summary

Net Buyer: 49,000 shares

Net Buy 2 txns

Insider Blume-Jensen Peter, Masson Kristina

Role President and CEO | EVP - Business Operations

Bought 49,000 shs ($82K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	49,000	$1.676	$82K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,095,771 shares (Direct); Common Stock — 314,706 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.
2. F2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. F3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Acrivon Therapeutics (ACRV) report on this Form 4?

The Form 4 reports that President and CEO Dr. Peter Blume-Jensen purchased 49,000 shares of Acrivon Therapeutics common stock on January 14, 2026 in an open-market transaction coded "P" for purchase.

At what price did the ACRV insider shares trade in this purchase?

The reported weighted average purchase price was $1.676 per share, with multiple trades executed at prices ranging from $1.66 to $1.68 per share.

How many Acrivon (ACRV) shares does Peter Blume-Jensen own after the reported transaction?

After the transaction, Dr. Peter Blume-Jensen is shown as directly owning 2,095,771 shares of Acrivon Therapeutics common stock.

What indirect Acrivon share holdings are reported for Kristina Masson?

The filing lists 314,706 shares of Acrivon common stock held indirectly, attributed to co-founder and EVP Dr. Kristina Masson, with ownership coded as indirect (I) and described in a footnote.

How do Peter Blume-Jensen and Kristina Masson treat each other’s ACRV holdings in this Form 4?

Footnotes explain that the shares held by Dr. Blume-Jensen are also reported for Dr. Masson, but she disclaims beneficial ownership of them except for her pecuniary interest, and vice versa for the shares held by Dr. Masson.

Was the ACRV insider transaction completed under a 10b5-1 trading plan?

The form includes a checkbox reference for Rule 10b5-1 trading plans, but the provided excerpt does not indicate that this particular purchase was made under such a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 04:02 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		P		49,000	A	$1.676(1)	2,095,771	D(2)
Common Stock								314,706	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.

2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	01/16/2026
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.